Kraig Biocraft Laboratories Establishes Homozygosity and Confirms BAM 1 Hybrid Ready for Spring Production Trial

ANN ARBOR, Mich., – February 27, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), announces that it has achieved homozygosity for the spider silk gene in both of the parental strains for its new production hybrid. Establishing homozygosity for the targeted gene in both parental strains means that the Company’s new BAM 1 hybrid production system is optimized for recombinant spider silk production.

The BAM 1 hybrid represents the Company’s latest innovation in the commercialization of recombinant spider silk technology. Achieving homozygosity for both BAM 1 parental strains is another significant milestone in the commercialization of recombinant spider silk. The reason homozygosity is important is because it results in higher levels of spider silk protein expression.

“Our team set an aggressive deadline for achieving homozygosity in the BAM 1 hybrid ahead of our spring production trials,” said CEO and Founder, Kim Thompson. “Today, I am pleased to report they met that goal and that BAM 1 hybrids, which will be our primary production strain for the upcoming production season, is now optimized for recombinant spider silk expression. Our team continues to hit its marks, and I am looking forward to a very exciting year for Kraig Labs and the commercial launch of our revolutionary spider silk technology.” 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (, a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

Kraig Biocraft Laboratories, Inc.

2723 South State Street Suite 150
Ann Arbor, Michigan 48104

Phone: (734) 619-8066

Corporate Website: